التفاصيل البيبلوغرافية
| العنوان: |
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. |
| المؤلفون: |
Grünwald, Viktor, Powles, Thomas, Masatoshi Eto, Kopyltsov, Evgeny, Sun Young Rha, Porta, Camillo, Motzer, Robert, Hutson, Thomas E., Méndez-Vidal, María José, Sung-Hoo Hong, Winquist, Eric, Goh, Jeffrey C., Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E., Perini, Rodolfo, Cixin He, Okpara, Chinyere E., McKenzie, Jodi |
| المصدر: |
Frontiers in Oncology; 2024, p1-2, 2p |
| مصطلحات موضوعية: |
RENAL cell carcinoma, SUNITINIB, MEDICAL sciences |
| مستخلص: |
This document is a corrigendum for an article titled "Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms." The corrigendum acknowledges errors in the legend for Figure 3 and Supplementary Table 1, which resulted in the omission of clarification regarding the calculation of objective response rates and complete response rates. The corrected legend and figures have been provided. Additionally, a correction has been made to a sentence in Section 3.2.3 regarding complete response rates. The authors apologize for the errors and state that they do not affect the scientific conclusions of the article. [Extracted from the article] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder